Newton Fund - DEVELOPMENT OF DIFFERENTIATED PRODUCT CONCEPTS FOR INSULIN GLARGINE

低成本胰岛素产品的可用性，特别是可以在冷链外分销和使用的产品，对于开发有效的医疗保健系统，以应对糖尿病发病率的快速增长至关重要。该项目将联合收割机Arecor和Cadila制药公司的专业知识和技术，开发一种创新的、低成本的基础胰岛素产品，可以在冷链外分销和使用。此外，将采用经验证的技术延长甘精胰岛素的作用持续时间，对控制低血糖具有有益效果。该项目的范围将允许配方开发和优化、稳定性测试和临床前开发。在项目成功完成后，项目合作伙伴将推进资产的临床开发和商业化。最终产品将利用Arecor的专有配方技术和Cadila在治疗开发和商业化方面的出色记录，将代表一个有吸引力的商业机会，并对印度的经济发展和社会福利产生强烈的积极影响。

Availability of low cost insulin products, particularly products that can be distributed and used outside the coldchain is critical to developing an effective healthcare system that can deal with the rapidly increasing incidenceof diabetes. This project will combine the expertise and technologies of Arecor and Cadila Pharmaceuticals todevelop a innovative, low cost basal insulin product that can be distributed and used outside the cold chain. Inaddition validated technology will be employed to extend the duration of action of insulin glargine withbeneficial consequences to the control of hypoglycaemia. The scope of the project will allow formulationdevelopment and optimisation, stability testing and pre-clinical development. Following successful completionof the project, the project partners will progress the asset into clinical development and commercialisation. Thefinal product, which will draw on Arecor’s proprietary formulation technologies and Cadila’s excellent trackrecord in therapeutic development and commercialisation, will represent an attractive commercial opportunityas well as having a strong positive impact on the economic development and social welfare in India.